Literature DB >> 9143680

Human T cell leukemia virus type I (HTLV-I) and human diseases.

T Uchiyama1.   

Abstract

HTLV-I infection is causally associated with a variety of human diseases including leukemia/lymphoma, myelopathy, uveitis, and arthropathy. Tax protein of HTLV-I, which is considered oncogenic, binds to transcription factors or other cytoplasmic cellular molecules involved in the fundamental cell function and thereby induces cellular changes. The interaction between HTLV-I-infected cells with dysregulated function and different kinds of cells in the host, such as lymphocytes and vascular endothelial cells through viral peptides, antigen receptors cell adhesion molecules, and cytokines, appears to be one of the basic mechanisms underlying the development of HTLV-I-associated diseases. This interaction may play a major role in determining tumorigenicity and in forming clinical features of the diseases. The in vivo cell proliferation model of HTLV-I-infected cells using severe combined immunodeficient (SCID) mice can differentiate tumorigenicity from cell immortalization in vitro. The OX40 and its ligand gp34, which are induced by HTLV-I infection and directly mediate the adhesion between HTLV-I-infected T cells and vascular endothelial cells, may be critically involved in the localization and proliferation of HTLV-I-infected cells in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9143680     DOI: 10.1146/annurev.immunol.15.1.15

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  110 in total

Review 1.  HTLV-1 infections.

Authors:  C R Bangham
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

2.  Human T-lymphotropic virus type 1 open reading frame I p12(I) is required for efficient viral infectivity in primary lymphocytes.

Authors:  B Albrecht; N D Collins; M T Burniston; J W Nisbet; L Ratner; P L Green; M D Lairmore
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Discordance between bovine leukemia virus tax immortalization in vitro and oncogenicity in vivo.

Authors:  J C Twizere; P Kerkhofs; A Burny; D Portetelle; R Kettmann; L Willems
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 4.  Molecular mechanisms in lymphocyte activation and growth.

Authors:  D W Ballard
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

5.  Human T-cell lymphotropic virus type 1 p12(I) expression increases cytoplasmic calcium to enhance the activation of nuclear factor of activated T cells.

Authors:  Wei Ding; Björn Albrecht; Robert E Kelley; Natarajan Muthusamy; Seung-Jae Kim; Ruth A Altschuld; Michael D Lairmore
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 6.  Human T-lymphotropic virus type 1 (HTLV-1): persistence and immune control.

Authors:  Charles R M Bangham
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

7.  Upregulation of human T-cell leukemia virus type 1 antisense transcription by the viral tax protein.

Authors:  Sébastien Landry; Marilène Halin; Amandine Vargas; Isabelle Lemasson; Jean-Michel Mesnard; Benoit Barbeau
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

8.  Human T-cell lymphotropic virus type 1 p12I enhances interleukin-2 production during T-cell activation.

Authors:  Wei Ding; Seung-Jae Kim; Amrithraj M Nair; Bindhu Michael; Kathleen Boris-Lawrie; Adam Tripp; Gerold Feuer; Michael D Lairmore
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Human T-cell leukemia virus type 1 Tax induction of NF-kappaB involves activation of the IkappaB kinase alpha (IKKalpha) and IKKbeta cellular kinases.

Authors:  R Geleziunas; S Ferrell; X Lin; Y Mu; E T Cunningham; M Grant; M A Connelly; J E Hambor; K B Marcu; W C Greene
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

Review 10.  Immunologic control of human T-cell leukemia virus type I and adult T-cell leukemia.

Authors:  Mari Kannagi
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.